New drug cocktail aims to shrink stomach tumors before surgery

NCT ID NCT07314203

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether adding an immunotherapy drug (adebrelimab) and a targeted therapy (apatinib) to standard chemotherapy (SOX) can improve outcomes for people with locally advanced stomach cancer that cannot be removed right away. The study will enroll 118 participants and measure how often the cancer completely disappears after treatment. The goal is to see if this combination can make surgery more effective and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
adebrelimab (immunotherapy), apatinib mesylate (targeted therapy), and SOX chemotherapy (S-1 and oxaliplatin)
What this could lead to
If successful, this could improve the chance of eliminating visible cancer before surgery, potentially leading to better long-term outcomes for people with locally advanced gastric cancer.
What could go wrong
This is a Phase 3 trial, but it is not yet recruiting and has only 118 participants. Adding multiple drugs may increase side effects, and the benefit over standard treatment is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, 350001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.